Image

Early Environmental and Maternal Determinants of Airway Inflammation in Wheezing Disorders in Infants

Early Environmental and Maternal Determinants of Airway Inflammation in Wheezing Disorders in Infants

Recruiting
100 years and younger
All
Phase N/A
Background

Lung development and growth is a complexly orchestrated process starting prenatally in the first embryonic weeks, and ending, with the last important stages of alveolarization from the 24th week onwards. By the time of birth, around one third of the total amount of alveoli has developed, while the rest develops during infancy and childhood. After birth, lung volume, airways and the gas-exchanging surface increase by a multiple, reaching the maximum lung size at around 25 years of age. A comprehensive understanding of lung growth and development is crucial in order to understand the pathophysiology of lung diseases. During childhood and ongoing lung growth, an important amount of respiratory diseases might develop.

Objectives

Longitudinal assessment of lung growth and development, to examine respiratory morbidity such as Asthma and allergy, and the complex relationship between associated Risk factors mainly genetic predisposition and environmental factors on both lung development and subsequent respiratory morbidity, Therefore, longitudinal data on lung function and structure, on respiratory morbidity and on genetic, immunological, microbiological and environmental risk factors will be collected.

Methods

Recruitment and participation:

Participants will be recruited antenatal through advertisement placed at gynaecological Hospital in Bern and by obstetricians or midwives. Interested participants can get further information about the study by telephone from study nurses, as well as during the baseline visit at the University Children's Hospital in Bern, respectively. Mothers with a high risk of a preterm delivery will be informed by clinical Investigators at the Department of Obstetrics of the University Hospital Bern. Preterm infants, which receive ventilatory support over a long period are at Risk for chronical lung diseases in early childhood, named bronchopulmonary dysplasia (BPD). The recruitment of this infants will take place at the neonatology intensive care unit by clinical Investigators. On average 40 healthy children, 40 preterm children and 20 infants from risk pregnancies will be recruited as participants of the BILD cohort each year for Study Phase I. At 3, 6, 9, 12, 15 years and once after the 16th year of age the parents/participants will be asked again, if they would like to participate at the follow-up visits at the University Children's Hospital in Bern for the subsequent Study Phases II and III.

Information collected:

Lung function data:

  • Tidal breathing parameters (minute ventilation, respiratory rate, tidal volume, tidal expiratory flow, tidal inspiratory flow, time to peak expiratory flow) averaged over 100 breaths.
  • Multiple breath washout (FRC, LCI, moment ratios) and single breath washout (molar mass)
  • Fractional exhaled nitric oxide (marker of airway inflammation)
  • Spirometric forced expiratory volume loops (FVC, FEV1, PEF, MEF50)
  • Body plethysmography (airway resistance, lung volumes: TLC, FRC, RV)
  • Respiratory Rate over 60 seconds
  • Interrupter resistance measurement (RINT)
  • Volatile organic compounds
  • Forced oscillation technique (FOT)
  • Electrical impedance tomography (EIT)
  • Impedance plethysmography (IP)

Microbiological data:

  • Nasal swabs (respiratory virus and bacterial diagnostics, as well as host transcriptome Analysis)
  • Pharyngeal swabs (bacterial colonization and microbiota Analysis)
  • Anterior nasal and oropharyngeal swabs (viral, bacterial and host transcriptome Analysis)
  • Nasal brush
  • Sputum (to analyse the neutrophils)

Cord blood (mononuclear cells (CBMC) (e.g. lymphocytes)which regulate the innate and adaptive immunity)

Blood count (hemoglobin concentration, hematocrit, leukocyte number, lymphocyte number, lymphocyte count, eosinophil count, basophil count, monocyte count, promyelocyte count, myelocyte count, platelet count, immunoglobulin E Level, Interleukins, Granulocyte-Monocyte-Colony Forming Unit, Tumor Necrosis Factor alpha, Interferon gamma and Interferon lambda)

Urin (to estimate the tobacco exposure during pregnancy (amount of Cotinine) and the content of caffeine and Steroid profile)

Lung function MRI: functional and structural images of the lung

Environmental pollution (Level of particulate matter <10um, Nitrogen dioxide, ozone and particulate matter <2.5um)

Skin-Prick Test (test for pollen, trees, house dust mite, cat and dog)

Questionnaires (to assess quality of life)

Medical history (information on respiratory Symptoms, pulmonary exacerbations, hospitalisations and regular therapy)

Study database:

All study data is recorded in an Access-database with SQL Servers by electronic Case Report Forms. The database is accordant to the HFG and was adapted together with the CTU.

Funding

Schweizerischer Nationalfonds (SNF) and Departement Lehre und Forschung of the Inselspital Bern.

Study details
    Healthy Volunteers

NCT04286464

University Hospital Inselspital, Berne

19 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.